ArticleTranslational psychiatry2026
Mapping lncRNAs onto multilevel mRNA co‑expression modules in autism.
Article in Translational psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autism spectrum disorder (ASD) involves heterogeneous genetic and transcriptomic alterations, but how these changes are organized across hierarchical co-expression scales and linked to long noncoding RNAs (lncRNAs) remains incompletely understood. Here, we present Minimum Span Clustering Network (MSCN), an unsupervised, deterministic framework that constructs traceable multilevel mRNA co-expression hierarchies without requiring soft-thresholding powers, fixed module numbers, cut heights, or stochastic initialization. Applied to two independent ASD brain transcriptome cohorts, MSCN reveals hierarchical gene modules across four resolution levels, enabling the detection of transcriptional patterns ranging from low-level, specific signals to high-level, broader biological pathways. We uncovered modules enriched in neuronal/axonal, developmental, and immune-related pathways, reflecting interconnected neurodevelopmental and immune-dysregulation programs in ASD. Cross-method comparisons showed that MSCN complements WGCNA and MEGENA by preserving biologically concordant modules while providing an explicit parent-child hierarchy; simulation and benchmark analyses supported comparable module recovery, preservation, and enrichment performance. By mapping lncRNAs to MSCN-derived mRNA modules, we identified lncRNAs associated with ASD-related mRNA modules and evaluated them as candidate statistical mediators in downstream transcription factor (TF)-lncRNA-mRNA analyses. This analysis identified over 11,000 candidate TF-lncRNA-mRNA axes, including 644 axes involving 46 SFARI score 1 or 2 genes, four of which were syndromic genes, and 12 named lncRNA mediators. External transcriptomic evaluation further supported 789 axes, including representative HIF1A-STXBP5-AS1-CADPS, E2F1-PART1-SCN2A, and RELA-RFPL1S-GRIN2A relationships. Together, these findings establish MSCN as a scalable framework for decomposing ASD mRNA co-expression architecture, provide a hypothesis-generating resource linking coding and noncoding transcriptomic alterations, and help prioritize these relationships for future validation.
Indexed as
Identifiers
42443147What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.